ReviewFrontiers in medicine2026
The COPD-driven "lung-eye axis": mechanisms and clinical evidence of ocular disease.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD is a chronic systemic disease marked by ongoing airflow obstruction, sustained inflammation, and increased oxidative stress, whose pathological impact extends far beyond the lungs. Growing data suggest that COPD impacts the eye via chronic systemic inflammation, intermittent or persistent hypoxia, oxidative stress, and endothelial dysfunction, establishing a cross-system pathological connection termed the "lung-eye axis." Evidence from clinical and experimental studies indicates potential associations between COPD and key ophthalmic conditions, such as dry eye disease, cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration. The underlying mechanisms largely involve the retina and optic nerve, which rely heavily on oxygenation and microvascular homeostasis, highlighting them as prime ocular targets of COPD systemic effects. The application of noninvasive imaging, such as OCT and OCTA, offers quantitative and objective preliminary evidence for the lung-eye axis, indicating that ocular imaging could function as a surrogate marker of systemic disease burden in COPD. Despite being largely cross-sectional and methodologically constrained, the proposed "COPD-driven lung-eye axis" framework offers a cross-organ perspective for understanding the systemic characteristics of COPD. There is an urgent need for large, prospective, multicenter studies combining pulmonary function tests, blood gas measurements, inflammatory biomarker profiling, and multimodal ocular imaging to establish causal links and clinical utility, providing novel strategies for precision stratification and early intervention of COPD-related systemic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.